{"id":"dobutamine","rwe":[{"pmid":"41906583","year":"2026","title":"An 11-Year-Old Athlete With Dynamic Stenosis of Coronary Artery Anomaly With Normal FFR-Dobutamine But Abnormal iFR-Dobutamine.","finding":"","journal":"JACC. Case reports","studyType":"Clinical Study"},{"pmid":"41891302","year":"2026","title":"Effect of preoperative vitamin B12 levels on postoperative outcomes in CABG patients.","finding":"","journal":"Turk gogus kalp damar cerrahisi dergisi","studyType":"Clinical Study"},{"pmid":"41883603","year":"2026","title":"Exercise stress cardiomyopathy-a case report.","finding":"","journal":"European heart journal. Case reports","studyType":"Clinical Study"},{"pmid":"41879241","year":"2026","title":"[Inotropic therapy in outpatients with worsening or advanced heart failure: literature evidence and comparison of Italian management models].","finding":"","journal":"Giornale italiano di cardiologia (2006)","studyType":"Clinical Study"},{"pmid":"41875020","year":"2026","title":"Association Between Ionized Calcium Concentrations During Weaning From Cardiopulmonary Bypass and Postoperative Low Cardiac Output Syndrome: A Retrospective Cohort Study.","finding":"","journal":"Anesthesia and analgesia","studyType":"Clinical Study"}],"_fda":{"id":"47bf8f3f-ee08-c235-e063-6394a90a96fb","set_id":"3418aa46-2d9a-39f3-e063-6294a90a2961","openfda":{"unii":["0WR771DJXV"],"route":["INTRAVENOUS"],"rxcui":["309985"],"spl_id":["47bf8f3f-ee08-c235-e063-6394a90a96fb"],"brand_name":["DOBUTAMINE IN DEXTROSE"],"spl_set_id":["3418aa46-2d9a-39f3-e063-6294a90a2961"],"package_ndc":["51662-1664-1"],"product_ndc":["51662-1664"],"generic_name":["DOBUTAMINE IN DEXTROSE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DOBUTAMINE HYDROCHLORIDE"],"manufacturer_name":["HF Acquisition Co. LLC, DBA HealthFirst"],"application_number":["NDA020201"],"original_packager_product_ndc":["0409-2346"]},"version":"2","warnings":["Increase in Heart Rate or Blood Pressure Dobutamine hydrochloride may cause a marked increase in heart rate or blood pressure, especially systolic pressure. Approximately 10% of adult patients in clinical studies have had rate increases of 30 beats/minute or more, and about 7.5% have had a 50-mm Hg or greater increase in systolic pressure. Usually, reduction of dosage reverses these effects. Because dobutamine facilitates atrioventricular conduction, patients with atrial fibrillation are at risk of developing rapid ventricular response. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine. Patients with pre-existing hypertension appear to face an increased risk of developing an exaggerated pressure response. Ectopic Activity Dobutamine may precipitate or exacerbate ventricular ectopic activity, but it rarely has caused ventricular tachycardia. Hypersensitivity Reactions suggestive of hypersensitivity associated with administration of Dobutamine in 5% Dextrose Injection, USP, including skin rash, fever, eosinophilia, and bronchospasm, have been reported occasionally. Dobutamine in 5% Dextrose Injection, USP contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people."],"overdosage":["Overdoses of dobutamine have been reported rarely. The following is provided to serve as a guide if such an overdose is encountered. Signs and Symptoms: Toxicity from dobutamine hydrochloride is usually due to excessive cardiac β-receptor stimulation. The duration of action of dobutamine hydrochloride is generally short (T½ = 2 minutes) because it is rapidly metabolized by catechol-O-methyltransferase. The symptoms of toxicity may include anorexia, nausea, vomiting, tremor, anxiety, palpitations, headache, shortness of breath, and anginal and nonspecific chest pain. The positive inotropic and chronotropic effects of dobutamine on the myocardium may cause hypertension, tachyarrhythmias, myocardial ischemia, and ventricular fibrillation. Hypotension may result from vasodilation. If the product is ingested, unpredictable absorption may occur from the mouth and the gastrointestinal tract. Treatment: To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians' Desk Reference (PDR). In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient. The initial actions to be taken in a dobutamine hydrochloride overdose are discontinuing administration, establishing an airway, and ensuring oxygenation and ventilation. Resuscitative measures should be initiated promptly. Severe ventricular tachyarrhythmias may be successfully treated with propranolol or lidocaine. Hypertension usually responds to a reduction in dose or discontinuation of therapy. Protect the patient's airway and support ventilation and perfusion. If needed, meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal. Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of dobutamine hydrochloride."],"description":["Dobutamine in 5% Dextrose Injection, USP is a sterile, nonpyrogenic, prediluted solution of dobutamine hydrochloride and dextrose in water for injection. It is administered by intravenous infusion. Each 100 mL contains dobutamine hydrochloride equivalent to 100 mg, 200 mg, or 400 mg of dobutamine; dextrose (derived from corn), hydrous 5 g in water for injection, with sodium metabisulfite 25 mg and edetate disodium, dihydrate 10 mg added as stabilizers; osmolar concentration, respectively, 263, 270, or 284 mOsmol/liter (calc.). The pH is 3.0 (2.5 to 5.5). May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. Dobutamine in 5% Dextrose Injection, USP is oxygen sensitive. Dobutamine Hydrochloride, USP is chemically designated (±)-4-[2-[[3-(p-hydroxyphenyl)-1-methylpropyl]amino]ethyl]-pyrocatechol hydrochloride. It is a synthetic catecholamine. Dextrose, USP is chemically designated D-glucose monohydrate (C6H12O6 • H2O), a hexose sugar freely soluble in water. It has the following structural formula: Water for Injection, USP is chemically designated H2O. The flexible plastic container is fabricated from a specially formulated CR3 plastic material. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. structure structure"],"precautions":["General During the administration of dobutamine, as with any adrenergic agent, ECG and blood pressure should be continuously monitored. In addition, pulmonary wedge pressure and cardiac output should be monitored whenever possible to aid in the safe and effective infusion of Dobutamine in 5% Dextrose Injection, USP. Hypovolemia should be corrected with suitable volume expanders before treatment with Dobutamine in 5% Dextrose Injection, USP is instituted. Animal studies indicate that dobutamine may be ineffective if the patient has recently received a β-blocking drug. In such a case, the peripheral vascular resistance may increase. No improvement may be observed in the presence of marked mechanical obstruction, such as severe valvular aortic stenosis. Do not administer unless solution is clear and container is undamaged. Discard unused portion. Usage Following Acute Myocardial Infarction: Clinical experience with dobutamine following myocardial infarction has been insufficient to establish the safety of the drug for this use. There is concern that any agent that increases contractile force and heart rate may increase the size of an infarction by intensifying ischemia, but it is not known whether dobutamine does so. Drug Interactions: There was no evidence of drug interactions in clinical studies in which dobutamine hydrochloride was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen. Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone. Concomitant use of dobutamine and catechol-O-methyltranferase (COMT) inhibitors (e.g., entacapone) may result in increased heart rate, arrhythmias, and changes in blood pressure. Carcinogenesis, Mutagenesis, Impairment of Fertility: Studies to evaluate the carcinogenic or mutagenic potential of dobutamine or the potential of the drug to affect fertility adversely have not been performed. Pregnancy: Reproduction studies performed in rats and rabbits have revealed no evidence of harm to the fetus due to dobutamine. The drug, however, has not been administered to pregnant women and should be used only when the expected benefits clearly outweigh the potential risks to the fetus. Pediatric Use: Dobutamine has been shown to increase cardiac output and systemic pressure in pediatric patients of every age group. In premature neonates, however, dobutamine is less effective than dopamine in raising systemic blood pressure without causing undue tachycardia, and dobutamine has not been shown to provide any added benefit when given to such infants already receiving optimal infusions of dopamine. Geriatric Use: Clinical studies of dobutamine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy."],"how_supplied":["DOBUTamine in 5% Dextrose Injection, USP is supplied in 250 LifeCare™ single-dose flexible containers as follows: NDC 51662-1664-2 250 mg/250 mL (1 mg/mL) Do not freeze. Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.] Distributed by HF Acquisition Co LLC dba HealthFirst"],"effective_time":"20260106","adverse_reactions":["Increased Heart Rate, Blood Pressure, and Ventricular Ectopic Activity: A 10- to 20-mm Hg increase in systolic blood pressure and an increase in heart rate of 5 to 15 beats/minute have been noted in most patients (see WARNINGS regarding exaggerated chronotropic and pressor effects). Approximately 5% of adult patients have had increased premature ventricular beats during infusions. These effects are dose related. Hypotension: Precipitous decreases in blood pressure have occasionally been described in association with dobutamine therapy. Decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to baseline values. In rare cases, however, intervention may be required and reversibility may not be immediate. Stress Cardiomyopathy: Stress cardiomyopathy has been reported with dobutamine in association with cardiac stress testing. Reactions at Sites of Intravenous Infusion: Phlebitis has occasionally been reported. Local inflammatory changes have been described following inadvertent infiltration. Miscellaneous Uncommon Effects: The following adverse effects have been reported in 1% to 3% of adult patients: nausea, headache, anginal pain, nonspecific chest pain, palpitations, and shortness of breath. Administration of dobutamine, like other catecholamines, has been associated with decreases in serum potassium concentrations, rarely to hypokalemic values."],"contraindications":["Dobutamine in 5% Dextrose Injection, USP is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine or any of its components."],"clinical_pharmacology":["Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the β-receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not cause the release of endogenous norepinephrine, as does dopamine. In animal studies, dobutamine produces less increase in heart rate and less decrease in peripheral vascular resistance for a given inotropic effect than does isoproterenol. In patients with depressed cardiac function, both dobutamine and isoproterenol increase the cardiac output to a similar degree. In the case of dobutamine, this increase is usually not accompanied by marked increases in heart rate (although tachycardia is occasionally observed), and the cardiac stroke volume is usually increased. In contrast, isoproterenol increases the cardiac index primarily by increasing the heart rate while stroke volume changes little or declines. Facilitation of atrioventricular conduction has been observed in human electrophysiologic studies and in patients with atrial fibrillation. Systemic vascular resistance is usually decreased with administration of dobutamine. Occasionally, minimum vasoconstriction has been observed. Most clinical experience with dobutamine is short-term, not more than several hours in duration. In the limited number of patients who were studied for 24, 48, and 72 hours, a persistent increase in cardiac output occurred in some, whereas output returned toward baseline values in others. The onset of action of Dobutamine in 5% Dextrose Injection, USP is within 1 to 2 minutes; however, as much as 10 minutes may be required to obtain the peak effect of a particular infusion rate. The plasma half-life of dobutamine in humans is 2 minutes. The principal routes of metabolism are methylation of the catechol and conjugation. In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine. The 3-O-methyl derivative of dobutamine is inactive. Alteration of synaptic concentrations of catecholamines with either reserpine or tricyclic antidepressants does not alter the actions of dobutamine in animals, which indicates that the actions of dobutamine are not dependent on presynaptic mechanisms. The effective infusion rate of dobutamine varies widely from patient to patient, and titration is always necessary (see DOSAGE AND ADMINISTRATION). At least in pediatric patients, dobutamine-induced increases in cardiac output and systemic pressure are generally seen, in any given patient, at lower infusion rates than those that cause substantial tachycardia (see PRECAUTIONS, Pediatric Use)."],"indications_and_usage":["Dobutamine in 5% Dextrose Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. Whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-AMP-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. In controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-AMP-dependent inotropes were consistently associated with increased risks of hospitalization and death. Patients with NYHA Class IV symptoms appeared to be at particular risk."],"spl_unclassified_section":["DOBUTamine in 5% Dextrose Injection, USP Flexible Plastic Container"],"dosage_and_administration":["Recommended Dosage Dobutamine in 5% Dextrose Injection, USP is administered intravenously through a suitable intravenous catheter or needle. A calibrated electronic infusion device is recommended for controlling the rate of flow in mL/hour or drops/minute. Infusion of dobutamine should be started at a low rate (0.5 to 1.0 µg/kg/min) and titrated at intervals of a few minutes, guided by the patient's response, including systemic blood pressure, urine flow, frequency of ectopic activity, heart rate, and (whenever possible) measurements of cardiac output, central venous pressure, and/or pulmonary capillary wedge pressure. In reported trials, the optimal infusion rates have varied from patient to patient, usually 2 to 20 µg/kg/min but sometimes slightly outside of this range. On rare occasions, infusion rates up to 40 µg/kg/min have been required to obtain the desired effect. Rates of infusion in mL/hour for dobutamine hydrochloride concentrations of 500, 1,000, 2,000 and 4,000 mg/L may be calculated using the following formula: This container system may be inappropriate for the dosage requirements of pediatric patients under 30 kg. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Dobutamine in 5% Dextrose Injection, USP solutions may exhibit a pink color that, if present, will increase with time. This color change is due to slight oxidation of the drug, but there is no significant loss of potency. Solutions containing dextrose should not be administered through the same administration set as blood, as this may result in pseudoagglutination or hemolysis. Do not add supplementary medications to Dobutamine in 5% Dextrose Injection, USP. Do not administer Dobutamine in 5% Dextrose Injection, USP simultaneously with solutions containing sodium bicarbonate or strong alkaline solutions. INSTRUCTIONS FOR USE To Open Tear outer wrap at notch and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Preparation for Administration (Use aseptic technique) 1. Close flow control clamp of administration set. 2. Remove cover from outlet port at bottom of container. 3. Insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. NOTE: See full directions on administration set carton. 4. Suspend container from hanger. 5. Squeeze and release drip chamber to establish proper fluid level in chamber. 6. Open flow control clamp and clear air from set. Close clamp. 7. Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture. 8. Regulate rate of administration with flow control clamp. WARNING: Do not use flexible container in series connections. DA"],"spl_product_data_elements":["DOBUTAMINE IN DEXTROSE DOBUTAMINE IN DEXTROSE DEXTROSE MONOHYDRATE SODIUM METABISULFITE SODIUM HYDROXIDE DOBUTAMINE HYDROCHLORIDE DOBUTAMINE WATER HYDROCHLORIC ACID EDETATE DISODIUM"],"package_label_principal_display_panel":["Label CARTON LABEL"]},"tags":[{"label":"beta-Adrenergic Agonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Beta-2 adrenergic receptor","category":"target"},{"label":"ADRB2","category":"gene"},{"label":"ADRA1D","category":"gene"},{"label":"SLC6A3","category":"gene"},{"label":"C01CA07","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Cardiac Decompensation","category":"indication"},{"label":"Cardiac Decompensation Post Cardiac Surgery","category":"indication"},{"label":"Cardiogenic shock","category":"indication"},{"label":"Decompensated cardiac failure","category":"indication"},{"label":"Organic Cardiac Disease","category":"indication"},{"label":"Stress echocardiography using dobutamine","category":"indication"},{"label":"Approved 1970s","category":"decade"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Agonists","category":"pharmacology"},{"label":"Adrenergic beta-1 Receptor Agonists","category":"pharmacology"},{"label":"Adrenergic beta-Agonists","category":"pharmacology"},{"label":"Cardiotonic Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"},{"label":"Sympathomimetics","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"836 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"583 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"488 reports"},{"date":"","signal":"CARDIOGENIC SHOCK","source":"FDA FAERS","actionTaken":"446 reports"},{"date":"","signal":"MULTIPLE ORGAN DYSFUNCTION SYNDROME","source":"FDA FAERS","actionTaken":"404 reports"},{"date":"","signal":"SEPSIS","source":"FDA FAERS","actionTaken":"387 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"385 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"331 reports"},{"date":"","signal":"GENERAL PHYSICAL HEALTH DETERIORATION","source":"FDA FAERS","actionTaken":"330 reports"},{"date":"","signal":"STRESS","source":"FDA FAERS","actionTaken":"321 reports"}],"drugInteractions":[{"url":"/drug/linezolid","drug":"linezolid","action":"Avoid combination","effect":"May interact with Linezolid","source":"DrugCentral","drugSlug":"linezolid"}],"commonSideEffects":[{"effect":"Appendicolith","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Multiple organ dysfunction syndrome","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Appendicitis","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Ventricular fibrillation","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Ascites","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Stress","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Blood phosphorus increased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Abdominal distension","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Sepsis","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hyponatraemia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Cardiogenic shock","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"General physical health deterioration","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Toxic epidermal necrolysis","drugRate":"","severity":"common","_validated":false,"_confidence":0.3}],"contraindications":["Aortic valve stenosis","Atrial fibrillation","Hypertensive disorder","Hypokalemia","Hypovolemia","Idiopathic hypertrophic subaortic stenosis","Myocardial infarction","Ventricular premature beats"],"specialPopulations":{"Pregnancy":"There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy with caution.","Geriatric use":"Of the 1893 patients in clinical studies who were treated with dobutamine, 930 (49.1%) were 65 and older. No overall differences in safety or effectiveness were observed between these and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.In general, dose selection for an elderly patient should be cautious, usually starting at a lower dose.","Paediatric use":"Dobutamine has been shown to increase cardiac output and systemic pressure in pediatric patients of every age group. In premature neonates, however, dobutamine is less effective than dopamine in raising systemic blood pressure without causing undue tachycardia, and dobutamine has not been shown to provide any added benefit when given to such infants already receiving optimal infusions of dopamine."}},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:53:51.691833","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DOBUTAMINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:47:26.690707+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:47:32.530654+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:47:25.808345+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DOBUTAMINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:47:32.848491+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:47:21.490096+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:47:21.490129+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:47:34.328977+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Beta-2 adrenergic receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:47:33.879501+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200418/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:47:33.549296+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA020201","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:47:21.490134+00:00"}},"allNames":"dobutamine hydrochloride in dextrose 5% in plastic container","offLabel":[],"synonyms":["dobutamine","dobutamine hydrochloride","dobutamine HCl"],"timeline":[{"date":"1978-07-18","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"1993-10-19","type":"positive","source":"FDA Orange Book","milestone":"Dobutamine Hydrochloride In Dextrose 5% approved — EQ 50MG BASE/100ML"},{"date":"1994-07-07","type":"positive","source":"FDA Orange Book","milestone":"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container approved — EQ 400MG BASE/100ML"},{"date":"2022-12-21","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 10 manufacturers approved"}],"approvals":[{"date":"1978-07-18","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container","ecosystem":[{"indication":"Cardiac Decompensation","otherDrugs":[],"globalPrevalence":null},{"indication":"Cardiac Decompensation Post Cardiac Surgery","otherDrugs":[],"globalPrevalence":null},{"indication":"Cardiogenic shock","otherDrugs":[],"globalPrevalence":3200000},{"indication":"Decompensated cardiac failure","otherDrugs":[{"name":"amrinone","slug":"amrinone","company":"Sanofi Aventis Us"},{"name":"dopamine","slug":"dopamine","company":""},{"name":"furosemide","slug":"furosemide","company":"Sanofi Aventis Us"},{"name":"milrinone","slug":"milrinone","company":"Sanofi Aventis Us"}],"globalPrevalence":null},{"indication":"Organic Cardiac Disease","otherDrugs":[],"globalPrevalence":null},{"indication":"Stress echocardiography using dobutamine","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Beta-2 adrenergic receptor","novelty":"Follow-on","targets":[{"gene":"ADRB2","source":"DrugCentral","target":"Beta-2 adrenergic receptor","protein":"Beta-2 adrenergic receptor","isPrimary":true,"activityType":"EC50","activityValue":6.2},{"gene":"ADRA1D","source":"DrugCentral","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor"},{"gene":"SLC6A3","source":"DrugCentral","target":"Sodium-dependent dopamine transporter","protein":"Sodium-dependent dopamine transporter"},{"gene":"SLC6A2","source":"DrugCentral","target":"Sodium-dependent noradrenaline transporter","protein":"Sodium-dependent noradrenaline transporter"},{"gene":"CA2","source":"DrugCentral","target":"Carbonic anhydrase 2","protein":"Carbonic anhydrase 2"},{"gene":"CA5A","source":"DrugCentral","target":"Carbonic anhydrase 5A, mitochondrial","protein":"Carbonic anhydrase 5A, mitochondrial"},{"gene":"CA5B","source":"DrugCentral","target":"Carbonic anhydrase 5B, mitochondrial","protein":"Carbonic anhydrase 5B, mitochondrial"},{"gene":"SLC6A4","source":"DrugCentral","target":"Sodium-dependent serotonin transporter","protein":"Sodium-dependent serotonin transporter"},{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"}],"moaClass":"Adrenergic beta-Agonists","modality":"Small Molecule","drugClass":"beta-Adrenergic Agonist","explanation":"","oneSentence":"","technicalDetail":"Dobutamine is a non-selective beta-adrenergic agonist that stimulates the beta-1 and beta-2 adrenergic receptors, leading to increased heart rate, contractility, and cardiac output, as well as vasodilation and decreased peripheral resistance."},"commercial":{"launchDate":"1978","_launchSource":"DrugCentral (FDA 1978-07-18, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/937","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DOBUTAMINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DOBUTAMINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:44:15.461163","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:47:36.448026+00:00","fieldsConflicting":14,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"isoprenaline","drugSlug":"isoprenaline","fdaApproval":"1956-03-09","relationship":"same-class"},{"drugName":"norepinephrine","drugSlug":"norepinephrine","fdaApproval":"1950-07-13","patentExpiry":"Mar 8, 2041","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"dopamine","drugSlug":"dopamine","fdaApproval":"1974-02-25","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"phenylephrine","drugSlug":"phenylephrine","fdaApproval":"1952-01-21","patentExpiry":"Sep 26, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"metaraminol","drugSlug":"metaraminol","fdaApproval":"1954-09-29","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"methoxamine","drugSlug":"methoxamine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"mephentermine","drugSlug":"mephentermine","fdaApproval":"1951-12-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"midodrine","drugSlug":"midodrine","fdaApproval":"1996-09-06","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fenoldopam","drugSlug":"fenoldopam","fdaApproval":"1997-09-23","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"arbutamine","drugSlug":"arbutamine","fdaApproval":"1997-09-12","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"epinephrine","drugSlug":"epinephrine","fdaApproval":"1948-11-19","patentExpiry":"Oct 20, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ephedrine","drugSlug":"ephedrine","fdaApproval":"","patentExpiry":"May 16, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"droxidopa","drugSlug":"droxidopa","fdaApproval":"2014-02-18","genericCount":16,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"dobutamine","indications":{"approved":[{"name":"Cardiac Decompensation","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures."},{"name":"Cardiac Decompensation Post Cardiac Surgery","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Patients with cardiac decompensation post cardiac surgery."},{"name":"Cardiogenic shock","source":"DrugCentral","snomedId":89138009,"regulator":"FDA","eligibility":"Not specified","prevalenceClass":"1-5 / 10 000","globalPrevalence":3200000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency 2008[INST])"},{"name":"Decompensated cardiac failure","source":"DrugCentral","snomedId":195111005,"regulator":"FDA","eligibility":"Not specified"},{"name":"Organic Cardiac Disease","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Patients with organic heart disease."},{"name":"Stress echocardiography using dobutamine","source":"DrugCentral","snomedId":703338002,"regulator":"FDA","eligibility":"Not specified"}],"offLabel":[],"pipeline":[]},"_fixedFields":["primaryTarget"],"currentOwner":"Lilly","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"isoprenaline","brandName":"isoprenaline","genericName":"isoprenaline","approvalYear":"1956","relationship":"same-class"},{"drugId":"norepinephrine","brandName":"norepinephrine","genericName":"norepinephrine","approvalYear":"1950","relationship":"same-class"},{"drugId":"dopamine","brandName":"dopamine","genericName":"dopamine","approvalYear":"1974","relationship":"same-class"},{"drugId":"phenylephrine","brandName":"phenylephrine","genericName":"phenylephrine","approvalYear":"1952","relationship":"same-class"},{"drugId":"metaraminol","brandName":"metaraminol","genericName":"metaraminol","approvalYear":"1954","relationship":"same-class"},{"drugId":"methoxamine","brandName":"methoxamine","genericName":"methoxamine","approvalYear":"","relationship":"same-class"},{"drugId":"mephentermine","brandName":"mephentermine","genericName":"mephentermine","approvalYear":"1951","relationship":"same-class"},{"drugId":"midodrine","brandName":"midodrine","genericName":"midodrine","approvalYear":"1996","relationship":"same-class"},{"drugId":"fenoldopam","brandName":"fenoldopam","genericName":"fenoldopam","approvalYear":"1997","relationship":"same-class"},{"drugId":"arbutamine","brandName":"arbutamine","genericName":"arbutamine","approvalYear":"1997","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07179276","phase":"NA","title":"Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2026-03-15","conditions":["Sepsis - to Reduce Mortality in the Intensive Care Unit","Septic Shock"],"enrollment":750,"completionDate":"2027-12-31"},{"nctId":"NCT07432620","phase":"","title":"Artificial Intelligence Stress Echo (FINESSE) Project","status":"ACTIVE_NOT_RECRUITING","sponsor":"Milton Keynes University Hospital NHS Foundation Trust","startDate":"2019-06-07","conditions":["Coronary Artery Disease","Chest Pain","Myocardial Ischemia","Angina Pectoris","Myocardial Infarction (MI)"],"enrollment":2281,"completionDate":"2028-10"},{"nctId":"NCT07416331","phase":"","title":"Impact Of Using LevosemidanVersus DobutamineOn Right Ventricular Function In AdultPatients Undergoing Elective Valve Replacement Surgery","status":"COMPLETED","sponsor":"Helwan University","startDate":"2024-08-01","conditions":["Right Ventriculaire Dysfunction","Pulmonary Hypertension"],"enrollment":52,"completionDate":"2025-08-01"},{"nctId":"NCT07406477","phase":"PHASE2","title":"The PROTECT-HIE Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Alberta","startDate":"2026-05-01","conditions":["Hypoxic-ischemic Encephalopathy (HIE)"],"enrollment":40,"completionDate":"2029-04-30"},{"nctId":"NCT04766554","phase":"NA","title":"Cerebral Oxygen Saturation Monitoring In Cardiac Surgery (COSMICS)","status":"COMPLETED","sponsor":"Instituto Nacional de Cardiologia de Laranjeiras","startDate":"2021-05-19","conditions":["Cardiac Disease","Cognitive Dysfunction"],"enrollment":326,"completionDate":"2024-08-20"},{"nctId":"NCT07339449","phase":"NA","title":"Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients Undergoing Major Abdominal Procedures - A Pilot Study","status":"RECRUITING","sponsor":"University Hospital Dubrava","startDate":"2025-08-01","conditions":["Major Abdominal Surgeries","Mechanical Ventilation"],"enrollment":100,"completionDate":"2027-06-30"},{"nctId":"NCT07305922","phase":"","title":"Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension","status":"RECRUITING","sponsor":"Region Stockholm","startDate":"2025-12-01","conditions":["Subarachnoid Aneurysm Hemorrhage","Cerebral Vasospasm After Subarachnoid Hemorrhage"],"enrollment":200,"completionDate":"2030-12-31"},{"nctId":"NCT06631482","phase":"NA","title":"Comparison Bewteen Intraoperative HPI vs. High Mean Arterial Pressure Threshold","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-09-16","conditions":["Hypotension During Surgery"],"enrollment":100,"completionDate":"2026-05-31"},{"nctId":"NCT06462313","phase":"NA","title":"Dobutamine for Management of Surgical Patients With Septic Shock","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-06-18","conditions":["Patients With Septic Shock","Surgical Patients","General Anesthesia"],"enrollment":584,"completionDate":"2025-11-15"},{"nctId":"NCT07144189","phase":"","title":"AI Assessment of Low-Gradient Aortic Stenosis Severity Based on Echocardiography","status":"RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2025-08-20","conditions":["Low-gradient Aortic Stenosis","Aortic Stenosis"],"enrollment":300,"completionDate":"2026-08-20"},{"nctId":"NCT04166331","phase":"PHASE3","title":"Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2020-09-20","conditions":["Sepsis","Cardiomyopathies","Hypoperfusion","Left Ventricular Systolic Dysfunction"],"enrollment":136,"completionDate":"2025-07-01"},{"nctId":"NCT03621618","phase":"NA","title":"Clinical Assessment of Arterial Dynamic Elastance in ICU Patients, Dependent on Inotropic or Vasopressor Drugs.","status":"WITHDRAWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2019-03-31","conditions":["Sepsis","Cardiac Failure Acute"],"enrollment":0,"completionDate":"2023-06-02"},{"nctId":"NCT06969547","phase":"","title":"Mechanical Dyssynchrony and Microvascular Dysfunction by SPECT","status":"RECRUITING","sponsor":"Tomsk National Research Medical Center of the Russian Academy of Sciences","startDate":"2023-10-01","conditions":["Myocardial Blood Flow Reserve","Mechanical Dyssynchrony","Coronary Arterial Disease (CAD)"],"enrollment":75,"completionDate":"2026-05-15"},{"nctId":"NCT03852147","phase":"NA","title":"Individualized Hemodynamic Optimization by Indirect Measurement of the Respiratory Quotient in Major Surgery: Prospective Randomized Multicentre Open-Label Study (OPHIQUE) Individualized Optimization by Indirect Measurement of the Respiratory Quotient","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2018-12-26","conditions":["Post-Op Complication","Respiratory Complication"],"enrollment":350,"completionDate":"2023-01-26"},{"nctId":"NCT07186062","phase":"","title":"Clinical Outcomes of Levosimendan Versus Dobutamine Versus Milrinone in Cases With Acute Decompensated Heart Failure With Impaired Renal Function","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-06-01","conditions":["Acute Decompensated Heart Failure (ADHF)","Cardiorenal Syndrome (CRS)"],"enrollment":60,"completionDate":"2024-06-01"},{"nctId":"NCT07175948","phase":"","title":"Outcome of Clinical Phenotypes of Pediatric Myocarditis at Assiut University Children Hospital","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-06-01","conditions":["Myocarditis","Myocarditis Acute"],"enrollment":100,"completionDate":"2027-08-01"},{"nctId":"NCT06384287","phase":"","title":"Peripheral Tissue Perfusion in Intensive Care","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-06-22","conditions":["Acute Circulatory Failure"],"enrollment":180,"completionDate":"2027-07"},{"nctId":"NCT04020172","phase":"PHASE1,PHASE2","title":"Improving Tissue Oxygenation in Breast Reconstruction Surgery","status":"COMPLETED","sponsor":"Dr. Glenio Mizubuti (MD, PhD)","startDate":"2019-07-12","conditions":["Perioperative Tissue Oxygenation"],"enrollment":40,"completionDate":"2024-05-01"},{"nctId":"NCT06973902","phase":"","title":"The Predictive Value of Dobutamine Echo-stress in the Clinical Response to CCM Therapy in Advanced HF","status":"RECRUITING","sponsor":"Quovadis Associazione","startDate":"2025-07-10","conditions":["Symptomatic Congestive Heart Failure"],"enrollment":120,"completionDate":"2028-12-31"},{"nctId":"NCT05350592","phase":"PHASE2","title":"Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2022-03-13","conditions":["Acute Myocardial Infarction","Cardiogenic Shock"],"enrollment":100,"completionDate":"2025-09-30"},{"nctId":"NCT06155812","phase":"PHASE2,PHASE3","title":"Multimodal Vasopressor Strategy in Septic Shock","status":"RECRUITING","sponsor":"University Medical Centre Maribor","startDate":"2023-12-23","conditions":["Shock, Septic"],"enrollment":80,"completionDate":"2026-11"},{"nctId":"NCT07000994","phase":"NA","title":"Dobutamine During Major Abdominal Surgery","status":"RECRUITING","sponsor":"University of Hamburg-Eppendorf","startDate":"2025-06-16","conditions":["Intraoperative Myocardial Depression"],"enrollment":100,"completionDate":"2026-04"},{"nctId":"NCT04682483","phase":"","title":"Cardiogenic Shock Working Group Registry","status":"RECRUITING","sponsor":"Tufts Medical Center","startDate":"2017-12-04","conditions":["Cardiogenic Shock"],"enrollment":5000,"completionDate":"2026-06-01"},{"nctId":"NCT05149196","phase":"NA","title":"Goal-directed Hemodynamic Management and Kidney Injury After Radical Nephrectomy or Nephroureterectomy","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-02-10","conditions":["Nephrectomy","Nephroureterectomy","Hemodynamic Management","Acute Kidney Injury","Chronic Kidney Diseases"],"enrollment":1724,"completionDate":"2034-12-30"},{"nctId":"NCT06478667","phase":"PHASE3","title":"The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-12-20","conditions":["Acute Myocarditis"],"enrollment":50,"completionDate":"2025-01-20"},{"nctId":"NCT05267886","phase":"PHASE4","title":"CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2022-03-05","conditions":["Shock, Cardiogenic"],"enrollment":346,"completionDate":"2026-12"},{"nctId":"NCT06920173","phase":"PHASE2","title":"Pulse Study: Peripheral Use of Low-dose Vasopressors for Safety and Efficacy in the Intensive Care Unit","status":"RECRUITING","sponsor":"Kingston Health Sciences Centre","startDate":"2025-02-03","conditions":["Shock","Peripheral Venous Catheterization","Central Venous Catheterization","Critically Ill Patients Admitted in ICU"],"enrollment":50,"completionDate":"2026-06-30"},{"nctId":"NCT06855758","phase":"NA","title":"Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-03-06","conditions":["Kidney Transplant","Delayed Graft Function","Intraoperative Hypotension"],"enrollment":150,"completionDate":"2027-06"},{"nctId":"NCT06878742","phase":"PHASE1,PHASE2","title":"Dose-finding for Dobutamine During Transitional Circulation in Very Preterm Infants","status":"RECRUITING","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2024-06-24","conditions":["Infant, Premature, Diseases","Circulatory and Respiratory Physiological Phenomena"],"enrollment":30,"completionDate":"2029-06"},{"nctId":"NCT06784570","phase":"PHASE2","title":"Impact of Perioperative Levosimendan on Patients Undergoing Cardiac Surgery With Low Ejection Fraction","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2021-01-01","conditions":["Cardiac Surgery","Low Ejection Fraction"],"enrollment":240,"completionDate":"2024-08-01"},{"nctId":"NCT05196815","phase":"NA","title":"Novel Echocardiographic and Invasive Haemodynamic Measurements in the Assessment of Patients Low Flow Low Gradient Aortic Stenosis Undergoing TAVI","status":"COMPLETED","sponsor":"The Royal Wolverhampton Hospitals NHS Trust","startDate":"2022-07-01","conditions":["Cardiovascular Abnormalities"],"enrollment":7,"completionDate":"2024-03-01"},{"nctId":"NCT01434251","phase":"NA","title":"Treatment of Hypotension of Prematurity (TOHOP)","status":"TERMINATED","sponsor":"UMC Utrecht","startDate":"2011-09-01","conditions":["Hypotension"],"enrollment":150,"completionDate":"2021-02-01"},{"nctId":"NCT04369573","phase":"PHASE4","title":"Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock","status":"TERMINATED","sponsor":"Niguarda Hospital","startDate":"2020-05-04","conditions":["Cardiogenic Shock"],"enrollment":100,"completionDate":"2024-10-14"},{"nctId":"NCT06465277","phase":"","title":"CMR Right Ventricular Contractile Reserve Following Lung Resection","status":"RECRUITING","sponsor":"Belfast Health and Social Care Trust","startDate":"2023-07-21","conditions":["Lung Cancer","Surgery","Anesthesia"],"enrollment":42,"completionDate":"2024-12"},{"nctId":"NCT00579241","phase":"NA","title":"Detection of Ultrasound Contrast Signals in the Cerebral Circulation","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2006-04-27","conditions":["Brain Vascular Disorders","Coronary Artery Disease"],"enrollment":0,"completionDate":"2009-12-12"},{"nctId":"NCT03469440","phase":"NA","title":"Goal Directed Therapy Aiming to Optimise Oxygen Central Venous Saturation in Children Undergoing Cardiac Surgery","status":"RECRUITING","sponsor":"Instituto do Coracao","startDate":"2018-02-01","conditions":["Heart; Dysfunction Postoperative, Cardiac Surgery","C.Surgical Procedure; Cardiac"],"enrollment":65,"completionDate":"2024-12"},{"nctId":"NCT06522594","phase":"PHASE2","title":"REMAP ECMO - Beta Receptor Modulation Trial","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2024-06-01","conditions":["Heart Failure","Cardiogenic Shock"],"enrollment":20,"completionDate":"2025-12-03"},{"nctId":"NCT06281067","phase":"NA","title":"Reassessment of myocardIAL Bridge TOwards PeRsOnalized Medicine","status":"RECRUITING","sponsor":"Azienda Ospedaliero Universitaria Maggiore della Carita","startDate":"2023-12-15","conditions":["Myocardial Bridge"],"enrollment":500,"completionDate":"2026-01-01"},{"nctId":"NCT02082483","phase":"NA","title":"Coronary Artery Disease Screening in Kidney Transplant Candidates","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2014-11","conditions":["End Stage Renal Disease","Coronary Artery Disease"],"enrollment":144,"completionDate":"2019-07-31"},{"nctId":"NCT04114799","phase":"NA","title":"Haemodynamical Optimization During Brain Surgery","status":"RECRUITING","sponsor":"University Hospital Hradec Kralove","startDate":"2019-04-01","conditions":["Brain Edema"],"enrollment":50,"completionDate":"2026-11-30"},{"nctId":"NCT06376318","phase":"","title":"Shock and Acute Conditions OutcOmes Platform","status":"ACTIVE_NOT_RECRUITING","sponsor":"Saint-Louis Hospital, Paris, France","startDate":"2024-01-01","conditions":["Circulatory Shock","Sepsis","Cardiogenic Shock","Major Trauma","Surgical Shock"],"enrollment":1000,"completionDate":"2026-01-01"},{"nctId":"NCT05210465","phase":"","title":"Objective Confirmation of thе Anti-ischemic Effectiveness of Trimetazidine 80mg Once Daily in Patients With Stable Angina Who Had a History of Myocardial Infarction (METHOD)","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2022-03-03","conditions":["Coronary Artery Disease"],"enrollment":36,"completionDate":"2024-04-17"},{"nctId":"NCT06372301","phase":"NA","title":"Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy","status":"RECRUITING","sponsor":"Steen Hvitfeldt Poulsen","startDate":"2024-04-02","conditions":["Transthyretin Amyloid Cardiomyopathy","Aortic Stenosis"],"enrollment":24,"completionDate":"2026-04-01"},{"nctId":"NCT06318260","phase":"PHASE1,PHASE2","title":"Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)","status":"RECRUITING","sponsor":"Steen Hvitfeldt Poulsen","startDate":"2024-04-08","conditions":["ATTR Amyloidosis Wild Type"],"enrollment":35,"completionDate":"2026-03"},{"nctId":"NCT00580437","phase":"NA","title":"Pre-operative Evaluation of Kidney & Pancreas Transplant Patients","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2003-05-02","conditions":["Kidney Transplantation","Pancreas Transplantation"],"enrollment":150,"completionDate":"2012-04-01"},{"nctId":"NCT05953142","phase":"PHASE2","title":"Use of Dobutamine in Patients With Sepsis and Maintained Hypoperfusion After Initial Volemic Resuscitation.","status":"NOT_YET_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2024-02-01","conditions":["Sepsis","Hypoperfusion","Hyperlactatemia"],"enrollment":120,"completionDate":"2026-03-31"},{"nctId":"NCT06210217","phase":"EARLY_PHASE1","title":"Effect of TEE-guided Non-fluid Limited Combined With Dobutamine on Hepatic Venous Blood Flow Spectrum","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2024-02-01","conditions":["Laparoscopic Hepatectomy"],"enrollment":51,"completionDate":"2024-04-07"},{"nctId":"NCT03021525","phase":"NA","title":"Individualized Perioperative Hemodynamic Goal-directed Therapy in Major Abdominal Surgery (iPEGASUS-trial)","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2017-08-29","conditions":["Hemodynamic Instability","Cardiac Output, High","Peroperative Complication"],"enrollment":380,"completionDate":"2023-08-26"},{"nctId":"NCT02327455","phase":"NA","title":"Integrated RF and B-mode Deformation Analysis for 4D Stress Echocardiography","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2023-07","conditions":["Coronary Artery Disease"],"enrollment":0,"completionDate":"2023-09"},{"nctId":"NCT01416077","phase":"PHASE4","title":"Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection","status":"COMPLETED","sponsor":"University Hospital, Linkoeping","startDate":"2011-10","conditions":["Esophageal Cancer"],"enrollment":64,"completionDate":"2015-10"},{"nctId":"NCT03661827","phase":"NA","title":"Dobutamine vs Adenosine CMR Study","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2019-02-05","conditions":["Heart Failure","Coronary Artery Disease","Cardiac MRI"],"enrollment":69,"completionDate":"2023-08-02"},{"nctId":"NCT03437421","phase":"NA","title":"Myocardial Function and Vitamin D Supplementation in Diabetes.","status":"COMPLETED","sponsor":"University of Avignon","startDate":"2018-02-04","conditions":["Diabetes Complications","Vitamin D Deficiency","Vitamin D Supplementation","Myocardial Dysfunction"],"enrollment":100,"completionDate":"2023-11-19"},{"nctId":"NCT02414321","phase":"","title":"The Role of the Pulmonary Vasculature in the Fontan Circulation","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2015-06","conditions":["Congenital Heart Disease","Fontan Operation","Pulmonary Vascular Resistance","Pulmonary Vascular Remodeling"],"enrollment":20,"completionDate":"2024-10-30"},{"nctId":"NCT00575549","phase":"","title":"Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo","status":"NO_LONGER_AVAILABLE","sponsor":"University of Nebraska","startDate":"","conditions":["Evaluation of Troponin I Levels"],"enrollment":0,"completionDate":""},{"nctId":"NCT00861848","phase":"","title":"Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2009-04-01","conditions":["Kawasaki Disease","Heart Disease"],"enrollment":124,"completionDate":"2019-03-01"},{"nctId":"NCT03996499","phase":"NA","title":"Myocardial Perfusion, Coronary Flow Reserve and Kinetic Analysis During Dobutamine Stress Echocardiography","status":"UNKNOWN","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2019-06-20","conditions":["Coronary Disease"],"enrollment":201,"completionDate":"2023-12-31"},{"nctId":"NCT05999487","phase":"NA","title":"Dobutamine Versus Milrinone in Management of Critically Ill Low Cardiac Output Pediatric Patients at Cairo University Children's Hospital","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-10","conditions":["Dobutamine, Milrinone , Pediatrics , Low Cardiac Output"],"enrollment":40,"completionDate":"2024-05"},{"nctId":"NCT05064202","phase":"NA","title":"Unloading in Heart Failure Cardiogenic Shock","status":"NOT_YET_RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2023-10-01","conditions":["Cardiogenic Shock"],"enrollment":456,"completionDate":"2028-07-01"},{"nctId":"NCT04893655","phase":"PHASE4","title":"Effect of Dobutamine on Hepatic Blood Flow During Goal-directed Hemodynamic Therapy","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2021-09-14","conditions":["General Anesthesia"],"enrollment":58,"completionDate":"2023-07-25"},{"nctId":"NCT04227821","phase":"","title":"Hemodynamic Optimalization in Pediatric Patients","status":"UNKNOWN","sponsor":"Brno University Hospital","startDate":"2023-09-01","conditions":["Hemodynamic Instability"],"enrollment":100,"completionDate":"2023-12-31"},{"nctId":"NCT05202938","phase":"","title":"eMESH Struct. 2022-23","status":"UNKNOWN","sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","startDate":"2022-07-21","conditions":["Septic Shock","Chronic Heart Failure"],"enrollment":32,"completionDate":"2024-07-21"},{"nctId":"NCT05944146","phase":"NA","title":"Consistency of Carotid Doppler Blood Flow and Thermodilution Technique","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2023-05-31","conditions":["Cardiac Surgery"],"enrollment":200,"completionDate":"2026-12-31"},{"nctId":"NCT05391087","phase":"NA","title":"Comparison Arterial Blood Pressure and Cardiac Index-based Hemodynamic Management on Postoperative Myocardial Injury","status":"COMPLETED","sponsor":"Istanbul Saglik Bilimleri University","startDate":"2022-06-01","conditions":["Myocardial Injury","Perioperative/Postoperative Complications"],"enrollment":100,"completionDate":"2023-06-30"},{"nctId":"NCT03107923","phase":"","title":"Better Patient Selection to Transcatheter Aortic Valve Implantation","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2017-04-26","conditions":["Aortic Valve Stenosis","Left Ventricular Dysfunction","Myocardial Fibrosis"],"enrollment":103,"completionDate":"2021-03-31"},{"nctId":"NCT02756000","phase":"NA","title":"Timing of Complete Revascularization for Multivessel Coronary Artery Disease in STEMI","status":"COMPLETED","sponsor":"Clinical Hospital Center Zemun","startDate":"2016-01","conditions":["Myocardial Infarction"],"enrollment":120,"completionDate":"2018-11"},{"nctId":"NCT03289728","phase":"NA","title":"Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2018-04-04","conditions":["Myocardial Infarction"],"enrollment":1756,"completionDate":"2024-06"},{"nctId":"NCT05195931","phase":"","title":"Cardiac Output in Heart Failure Patients With Mechanical Pumps","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2021-06-08","conditions":["Heart Failure, Systolic","Mechanical Circulatory Support","Cardiovascular Hemodynamics"],"enrollment":7,"completionDate":"2022-08-25"},{"nctId":"NCT05836233","phase":"","title":"Predictive Value of Vasodilator Challenge for Right Heart Failure After LVAD Implantation","status":"UNKNOWN","sponsor":"San Camillo Hospital, Rome","startDate":"2023-02-15","conditions":["Right Heart Failure"],"enrollment":150,"completionDate":"2025-08-01"},{"nctId":"NCT04742764","phase":"PHASE3","title":"Extracorporal Cytokin Removal in Septic Shock: a Prospective, Randomized, Multicenter Clinical Trial","status":"SUSPENDED","sponsor":"University of Pecs","startDate":"2024-01-01","conditions":["Septic Shock"],"enrollment":135,"completionDate":"2027-10-31"},{"nctId":"NCT05702333","phase":"","title":"Vasoactive-inotropic Support and Levosimendan Use After Lung Transplantation","status":"COMPLETED","sponsor":"Policlinico Hospital","startDate":"2017-02-01","conditions":["Lung Transplant; Complications"],"enrollment":150,"completionDate":"2022-07-31"},{"nctId":"NCT05797584","phase":"NA","title":"Right Ventricular Contractile Reserve in HF","status":"UNKNOWN","sponsor":"Istituto Auxologico Italiano","startDate":"2019-03-20","conditions":["Heart Failure"],"enrollment":60,"completionDate":"2026-03-20"},{"nctId":"NCT02240745","phase":"","title":"New Three-dimensional Methods of Analysis for the Detection of Coronary Artery Disease by Dobutamine Stress Echocardiography","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2014-11-30","conditions":["Coronary Artery Disease","Echocardiography, Stress"],"enrollment":100,"completionDate":"2016-11-30"},{"nctId":"NCT04089969","phase":"NA","title":"Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct","status":"WITHDRAWN","sponsor":"Corewell Health East","startDate":"2023-06","conditions":["Coronary Artery Disease","Acute Liver Failure","Liver Transplant"],"enrollment":0,"completionDate":"2024-06"},{"nctId":"NCT05674084","phase":"","title":"Vasopressor Support, Mean Arterial Pressure and Capillary Refill Time in Critically Ill Patients","status":"UNKNOWN","sponsor":"Medical University of Silesia","startDate":"2022-12-03","conditions":["Critical Illness"],"enrollment":150,"completionDate":"2023-12-31"},{"nctId":"NCT03846765","phase":"PHASE4","title":"Influence of Continuous Administration of Phenylephrine Versus Dobutamine on Spinal Oxygen Saturation, Measured With Near-infrared Spectroscopy (NIRS).","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2019-07-04","conditions":["Nfuence of Vasoactive Medication on Spinal Oxygenation"],"enrollment":36,"completionDate":"2022-11-10"},{"nctId":"NCT04792424","phase":"NA","title":"No Monitoring of Post-filter Ionized Calcium in Regional Citrate Anticoagulation","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2021-04-01","conditions":["Regional Citrate Anticoagulation","Ionized Calcium","Continuous Renal Replacement Therapy"],"enrollment":50,"completionDate":"2022-06-15"},{"nctId":"NCT05025644","phase":"PHASE4","title":"Quantitative Assessment of Hypertrophic Obstructive Cardiomyopathy With Intraoperative Three-dimensional Transesophageal Echocardiography Under Provocative Dobutamine Stress Test","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2023-03","conditions":["Hypertrophic Obstructive Cardiomyopathy"],"enrollment":60,"completionDate":"2024-11"},{"nctId":"NCT05594342","phase":"PHASE3","title":"Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support","status":"UNKNOWN","sponsor":"The Young Investigator Group of Cardiovascular Research","startDate":"2022-07-01","conditions":["Heart Failure","Cardiogenic Shock","Ischemic Heart Disease"],"enrollment":200,"completionDate":"2023-01-01"},{"nctId":"NCT03585452","phase":"NA","title":"Effects of Dexmedetomidine on Cognitive Outcome and Brain Injury Markers","status":"COMPLETED","sponsor":"Michał Kowalczyk","startDate":"2018-08-01","conditions":["Cognitive Dysfunction"],"enrollment":23,"completionDate":"2019-03-31"},{"nctId":"NCT02346565","phase":"NA","title":"Stress Echocardiography Versus Exercise ECG (ExECG) in Women With Chest Pain","status":"COMPLETED","sponsor":"London North West Healthcare NHS Trust","startDate":"2015-01","conditions":["Coronary Artery Disease"],"enrollment":416,"completionDate":"2022-09"},{"nctId":"NCT05587400","phase":"NA","title":"Consistency of Electrical Cardiometry and Pulmonary Artery Catheter","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-07-27","conditions":["Pulmonary Arterial Hypertension","Right Ventricular Dysfunction"],"enrollment":199,"completionDate":"2024-12-31"},{"nctId":"NCT03505112","phase":"NA","title":"The Effect of Goal-directed Hemodynamic Therapy in Radical Cystectomy","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2018-04-20","conditions":["Bladder Cancer","Radical Cystectomy"],"enrollment":82,"completionDate":"2021-10-24"},{"nctId":"NCT00001638","phase":"","title":"Magnetic Resonance Imaging of the Blood Vessels of the Heart","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1997-09-29","conditions":["Heart Disease"],"enrollment":2916,"completionDate":"2009-08-03"},{"nctId":"NCT05430880","phase":"","title":"Cardiac Responsiveness Assessment by CO2","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2022-09-01","conditions":["VCO2 Variation in Intensive Care as a Marker of Fluid Responsiveness","Cardiac Index Variation Transpulmonary Thermodilution in Patients on Controlled Ventilation With Shock"],"enrollment":100,"completionDate":"2023-09-01"},{"nctId":"NCT03160846","phase":"","title":"The Inotrope Evaluation and Research Patient Registry","status":"COMPLETED","sponsor":"Coram Clinical Trials","startDate":"2014-08-25","conditions":["Heart Failure"],"enrollment":129,"completionDate":"2021-09-30"},{"nctId":"NCT05412303","phase":"","title":"Vaso-inotropic Score and ECMO-VA Support in Post-cardiotomy Cardiogenic Shock.","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2019-01-01","conditions":["EMCO-VA"],"enrollment":2769,"completionDate":"2021-12-31"},{"nctId":"NCT03617406","phase":"NA","title":"Volume Challenge Added to DSE in the Diagnosis of Severe LFLGAS","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2018-05-31","conditions":["Aortic Valve Stenosis"],"enrollment":50,"completionDate":"2020-12-31"},{"nctId":"NCT02361801","phase":"PHASE3","title":"Liberal Versus Restrictive Use of Dobutamine in Cardiac Surgery","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2015-02","conditions":["Cardiac Output, Low","Coronary Disease"],"enrollment":160,"completionDate":"2018-06"},{"nctId":"NCT02496260","phase":"","title":"Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2015-07","conditions":["Breast Cancer"],"enrollment":25,"completionDate":"2018-12"},{"nctId":"NCT05241912","phase":"EARLY_PHASE1","title":"Supernormal Oxygen Delivery for Patients With Severe Burns","status":"UNKNOWN","sponsor":"Guangzhou Red Cross Hospital","startDate":"2022-02-28","conditions":["Burn Surgery","Dobutamine"],"enrollment":100,"completionDate":"2023-06-01"},{"nctId":"NCT05221788","phase":"NA","title":"Effect of Goal-directed Hemodynamic Therapy on Short-term Postoperative Complications in Patients With Extensive Burns","status":"COMPLETED","sponsor":"Guangzhou Red Cross Hospital","startDate":"2020-01-01","conditions":["Hemodynamics"],"enrollment":100,"completionDate":"2021-12-01"},{"nctId":"NCT04249258","phase":"EARLY_PHASE1","title":"Dobutamine on the Cardiac Conduction System","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2020-01-14","conditions":["Arrhythmias, Cardiac"],"enrollment":37,"completionDate":"2021-11-20"},{"nctId":"NCT05081115","phase":"","title":"Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging","status":"RECRUITING","sponsor":"Fatebenefratelli Hospital","startDate":"2021-04-01","conditions":["Coronary Artery Disease","Heart Failure","Hypertrophic Cardiomyopathy","Congenital Heart Disease","Valvular Heart Disease","Post-chest Radio/Chemiotherapy","Heart Transplantation"],"enrollment":10000,"completionDate":"2030-12-31"},{"nctId":"NCT04508608","phase":"","title":"Scintigraphic Evaluation of Contractile and Coronary Reserve in Patients With Ischemic Cardiomyopathy","status":"COMPLETED","sponsor":"Tomsk National Research Medical Center of the Russian Academy of Sciences","startDate":"2018-09-01","conditions":["Ischemic Cardiomyopathy"],"enrollment":120,"completionDate":"2021-09-01"},{"nctId":"NCT05015829","phase":"","title":"Diagnostic Impact of Low-dose Dobutamine Echocardiography in Low-flow Low-gradient Aortic Stenosis","status":"UNKNOWN","sponsor":"Odense University Hospital","startDate":"2019-09-01","conditions":["Aortic Valve Stenosis","Valvular Stenosis","Valvular Heart Disease"],"enrollment":150,"completionDate":"2022-08-31"},{"nctId":"NCT02552238","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2015-10-12","conditions":["Coronary Artery Disease"],"enrollment":174,"completionDate":"2018-02-25"},{"nctId":"NCT02522481","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2015-09-24","conditions":["Coronary Artery Disease"],"enrollment":175,"completionDate":"2018-02-25"},{"nctId":"NCT04914481","phase":"","title":"Anatomic Stenosis Severity as a Prognostic Marker in Patients With Low-Flow Low-Gradient Aortic Stenosis Undergoing TAVI","status":"UNKNOWN","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2021-04-01","conditions":["Low-Flow, Low-Gradient Aortic Stenosis"],"enrollment":1500,"completionDate":"2025-12-31"},{"nctId":"NCT03813134","phase":"NA","title":"Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock","status":"UNKNOWN","sponsor":"University of Leicester","startDate":"2019-10-11","conditions":["Cardiogenic Shock"],"enrollment":428,"completionDate":"2024-02-01"},{"nctId":"NCT00074724","phase":"NA","title":"Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2003-05","conditions":["Cardiovascular Diseases","Coronary Disease","Heart Failure","Heart Failure, Congestive","Heart Diseases"],"enrollment":319,"completionDate":"2017-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Dobutamine"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"DOBUTAMINE HYDROCHLORIDE"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Dobutamine Hydrochloride in Dextrose"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Dobutamine"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"DOBUTAMINE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Dobutamine Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Dobutamine in Dextrose"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"DOBUTAMINE"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Dobutamine"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147822","MMSL":"2871","NDDF":"000614","UNII":"3S12J47372","VUID":"4019730","CHEBI":"CHEBI:4670","VANDF":"4017541","INN_ID":"3340","RXNORM":"203121","UMLSCUI":"C0012963","chemblId":"CHEMBL1200418","ChEMBL_ID":"CHEMBL926","KEGG_DRUG":"D00632","DRUGBANK_ID":"DB00841","PDB_CHEM_ID":" Y00","PUBCHEM_CID":"36811","SNOMEDCT_US":"26523005","IUPHAR_LIGAND_ID":"535","SECONDARY_CAS_RN":"49745-95-1","MESH_DESCRIPTOR_UI":"D004280"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Eli Lilly","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","clearance":"115.0 mL/min/kg"},"publicationCount":9734,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C01CA07","allCodes":["C01CA07"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 25","pmid":"41906583","title":"An 11-Year-Old Athlete With Dynamic Stenosis of Coronary Artery Anomaly With Normal FFR-Dobutamine But Abnormal iFR-Dobutamine.","journal":"JACC. Case reports"},{"date":"2026 Mar 27","pmid":"41891302","title":"Effect of preoperative vitamin B12 levels on postoperative outcomes in CABG patients.","journal":"Turk gogus kalp damar cerrahisi dergisi"},{"date":"2026 Mar","pmid":"41883603","title":"Exercise stress cardiomyopathy-a case report.","journal":"European heart journal. Case reports"},{"date":"2026 Apr","pmid":"41879241","title":"[Inotropic therapy in outpatients with worsening or advanced heart failure: literature evidence and comparison of Italian management models].","journal":"Giornale italiano di cardiologia (2006)"},{"date":"2026 Mar 24","pmid":"41875020","title":"Association Between Ionized Calcium Concentrations During Weaning From Cardiopulmonary Bypass and Postoperative Low Cardiac Output Syndrome: A Retrospective Cohort Study.","journal":"Anesthesia and analgesia"}],"companionDiagnostics":[],"genericManufacturers":10,"_genericFilersChecked":true,"genericManufacturerList":["Baxter Hlthcare","Dr Reddys","Hikma","Hospira","Luitpold","Slate Run Pharma","Teligent","Teva Parenteral","Watson Labs","Watson Labs Inc"],"status":"approved","companyName":"Lilly","companyId":"","modality":"Small molecule","firstApprovalDate":"1978","aiSummary":"","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1978-07-18T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1993-09-27T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":"NDA020255"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-12-02T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":"ANDA074086"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-02-26T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA074277"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1998-10-28T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":"NDA020201"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-12-21T00:00:00.000Z","mah":"SLATE RUN PHARMA","brand_name_local":null,"application_number":"ANDA216131"},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:47:36.448026+00:00","fieldsConflicting":14,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}